NEW YORK, August 14, 2025--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced the discontinuation of the clinical development program for SGR-2921, its CDC7 inhibitor, which was being ...
Market conditions remain tough, which is weighing on demand for both Schrödinger's software and drug discovery services. Investors continue to punish Schrödinger's investments in drug discovery, ...
Stochastic nonlinear wave equations and Schrödinger equations represent a fascinating confluence of probability theory and the analysis of partial differential equations. By incorporating random ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback